SITE015-0148

SITE015 (POL) › SITE015-0148

SITE015-0148

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2026-02-26

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-01-03 (study day 121); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.